

Index

Page numbers in bold type, e.g. 38–45, indicate detailed discussion of the topic.

A

accidents, 43–5, 131, 134–6, 202, 208, 212, 222; *see also* driving

acute health effects, 36, 38–45, 131, 134, 209, 212–14

acute psychological effects, 38, 45, 119, 213–14

addiction *see* drug dependence

administration, methods of, 6, 14, 38, 130, 135, 140, 228, 232; *see also* cannabis

smoking; injection; oral administration

administrative sanctions *see* civil sanctions

adolescents: accidents, 44; cannabis as

gateway drug, 104–14, 216; cannabis dependence, 75–6, 78, 125; cannabis use, 18–26, 28–9, 78, 90, 93, 96, 140, 159, 208;

cognitive effects, 125; complementary drug use, 153; crime, 237–9;

decriminalisation and use, xi, 222;

delinquency and crime, 124–5; deterrence, 2, 157; drug substitution, 145; effects of cannabis use, xii, 216; effects on

development, 101–25, 224; employment, 125; enforcement, 125, 168; health effects, 132; heavy users, 125; home cultivation, 210; interpersonal relationships, 121;

intoxication, 125; law reform and use, 198, 201–2, 209–10, 211–12, 223–5; life

opportunities, 125; mental health, 121–3, 125, 143–4; occupational performance, 120–1; problem behaviour, 116, 239;

psychological outcomes, 70, 115–25; psychosocial outcomes, 35, 216;

recreational use, 147; reproductive effects, 53; schizophrenia, 137; suicide, 123–4; *see also* disrespect for law; educational performance; young adults

adulthood, transition to, 103, 119–21, 163, 211, 223

adults: benefits of recreational cannabis use, 142, 153; cardiovascular effects, 61, 215;

cognitive effects, 119; crime, 124;

deterrence, 161, 164; legal use, 197–8;

patterns of use, 21–9; prohibition of use, 1; psychotic disorders, 96; *see also* young adults

adverse health effects, 1–5, 31–65, 130, 136, 138, 222, 225; alternative explanations, 34–5; education, 179–80; high-risk

groups, 132; prohibition and, 159, 216–17;

psychological effects, 69; *see also* acute health effects; chronic health effects

aerodigestive tract cancers, 47–9, 58, 64–5, 131, 135, 214

affective disorders, 122, 142–3

Africa, cannabis use in, 26–8

age: cannabis dependence and, 75; cannabis use and, 18–25, 26–7; early adolescent use, 125; first use, 104, 108–9, 113, 117–20,

124–5, 132–3, 216; legal drinking age, 144–5, 160; restrictions on use, 202, 205,

209–10, 218, 222

aggression *see* violence and aggression

AIDS *see* HIV-AIDS

alcohol: benefits of moderate use, 142–3; cognitive impairment, 85; crime, 236–8;

dependence, 71, 75, 77–8, 90, 98, 109, 122–5, 132, 135, 215; driving under the

influence (*see* driving); educational performance, 117–18; gateway hypothesis, 104, 106–7, 111–13, 216; health effects,

- 5–6, 129, 130–41, 213, 217; legal restrictions, 201–4, 207, 222; mental health benefits of moderate use, 153, 222; mental health of adolescents, 122, 219; patterns of use, 21–2, 160, 211; policy, x, 3–4, 223–4; pregnancy, 81; price, 208, 212; prohibition, 7, 157–8, 188, 190; psychomotor performance, 39–45; psychotic disorders, 89–91, 97–8; recreational use, 142; regulation, 201, 207, 222; risks, 136, 141; social cost, 208–9; substitution of cannabis for, 144–6; suicide, 123–4; use in combination with cannabis, 37, 41–5, 47–8, 56–8, 79, 81, 84, 89–91, 133, 136, 141, 208, 214; violence, 131
- allergies, 51
- amotivational syndrome, 70–1, 78, 119
- amphetamines, 37, 93, 104, 112–13, 189, 216
- analgesic effects, 60, 146–8, 151–2, 180–1, 219, 227–8, 230, 232–3
- animal evidence: cannabinoid receptors, 17; cardiovascular effects, 60; cellular processes, 46–7, 58; cross-sensitivity of drugs, 114; gastrointestinal effects, 65; health effects, 34–5, 37; immunological effects, 37, 50–2, 58, 214; medical uses, 147, 149–51, 153; pharmacology, 110–11, 114; reproductive effects, 53–5, 57, 214; tolerance, 72; toxicity, 39
- anti-convulsant use, 146–7, 149–50
- anti-emetic use, 65, 146–8, 150, 152–3, 180–1, 219, 227, 232–3
- anti-spasmodic use, 146–7, 149–50, 154, 180–1, 219, 232–3
- antisocial behaviour, 106, 115, 122, 125
- anxiety: adverse effect of cannabis use, 36, 38–9, 45, 73, 91, 98, 122, 131, 143, 213; benefit of moderate alcohol use, 142; medical uses, 151
- appetite stimulation, 17, 53, 65, 147–8, 152–4, 180, 215, 219, 227
- arthritis, 233
- Asia, cannabis use in, 26–8
- asthma, 132, 151
- attention, 38, 79, 81–3, 85, 115, 119, 131, 213, 215
- Australia: adolescent cannabis use, 104–5, 109, 115, 122–3; benefits of cannabis use, 142–4, 176; cannabis dependence, 74, 76, 78; cannabis use, 4, 23–5, 28–9, 159–62; car accidents, 42–3; crime, 236–8; drug dependence, 78; drug substitution, 146; immunological effects, 53; medical uses, 181, 219, 232–3, 234; methods of use, 14; policies, 1, 165–7, 169, 171, 174–9, 191–2, 196–7, 200, 210, 220–2; potency of cannabis, 133; price, 200; psychotic disorders, 90–1, 99; public health, 138–9, 201; schizophrenia, 99
- Austria, 167
- availability, 108, 112–13, 190, 205, 211
- B**
- behavioural effects, 59, 213, 215
- Belgium, x, 28
- benefits of cannabis use, xi, 129, 142–52, 153, 176, 219, 224
- birth defects, 55–7, 59, 134, 215
- birth weight, 56, 59, 131–2, 134, 137, 141, 215
- blackmarkets: alcohol prohibition, 157; cannabis prohibition, 1, 158, 172–5, 190, 224, 234; demand and potency, 133; economic costs, 166, 174; effects, 218–19; gateway hypothesis, 105; legal markets and, 197–200, 203–12, 221, 223, 225; violence and crime, 125, 238–9
- blood, 16–17, 42–5
- blood pressure, 39, 65, 135, 215
- bongs (water pipes), 14, 17, 25
- brain function, 16–17, 82, 84–5, 135, 150, 216
- bronchitis, 62–5, 131–2, 135–7, 141, 215
- C**
- caffeine use, 98
- Canada: cannabis dependence, 74; cannabis use in, 22–3, 26–9; driving accidents, 42; enforcement of prohibition, 165–6, 168, 170–1, 178–9; health costs, 139; medical uses, 233–4; policies, 1, 187, 197, 203; psychological effects, 81; schizophrenia, 99; taxation, 199, 207
- cancer *see* carcinogenicity; chemotherapy
- cannabidiol (CBD), 149–50
- cannabinoid receptors, 16–17, 50, 72, 86, 132, 147, 151, 216
- cannabinoids: absorption, 14–16; biology, 16–17; cancer, 46–7, 58; cannabis plant, 13; cardiovascular effects, 60–1, 65, 134; cognitive functioning, 80, 216; detection in bodily fluids, 15–16, 83; endogenous, 16–17; gastrointestinal effects, 65;

- immunological effects, 50–2, 214; medical uses (*see* medical uses); metabolism of, 15; motor accident drivers and victims, 42–3, 45, 214; pharmaceutical, 147–8, 153, 227–8, 230, 235; pharmacology, 110–11; physical effects, 39; potency (*see* potency); psychoactive effects, 13, 17, 87; psychomotor effects, 41–4; psychotic disorders, 99; reproductive effects, 53–5, 57, 59, 214; storage in body, 132–3, 236; tolerance and withdrawal, 72–3, 215; *see also* metabolites
- cannabis abuse, 73, 109, 123, 138–9, 143, 207, 209
- cannabis dependence, 70–8; adolescents, 75–6, 78, 125; consequences, 75–6; crime, 238; depression, 143; genetic vulnerability, 109; long-term users, 74, 141; policy and, 223–4; psychotic disorders, 90, 95; public health, 138–9; research, xiii, 73–4; risk, 74–5, 131–4, 137–8, 209, 215; suicide, 123; symptoms, 78; syndrome, 215; treatment, 76–8, 138, 215, 222; violence, 125
- cannabis products, 185, 210
- ‘cannabis psychosis’, 87, 88–9, 99
- cannabis smoke: immunological effects, 50, 52, 214; mutagenic and carcinogenic substances, 47, 58, 61–2, 64–5, 214, 228; respiratory effects, 61–5, 134, 215
- cannabis smoking, 6, 14–17, 25, 38; cancers, 47–9; cardiovascular effects, 60–1; heart rate, 39, 65; medical uses, 148, 151, 227–8, 230, 232–4; mortality, 43–4; respiratory effects, 61–5; withdrawal, 73; *see also* cannabis smoke
- car driving *see* driving
- carbon monoxide, 61, 63
- carcinogenicity: alcohol, 135; chronic cannabis use, 46–50, 131, 214–15; lung cancer, 65; respiratory cancers, 61–2, 64–5, 136–7, 141, 215; smoke, 58, 228; tobacco, 135–7
- cardiovascular effects, 39, 60–1, 65, 132, 134–6, 138, 142, 215
- Caribbean, 28, 70, 87–8; *see also* Jamaica
- causal inferences: crime, 236; educational performance, 116–17, 119; health effects, 6–7, 33–6, 37, 130, 134; psychological effects, 69; psychotic disorders, 87, 88, 137; social policy, 7; *see also* gateway hypothesis
- CBD (cannabidiol), 149–50
- cellular effects of chronic cannabis use, 46–50, 214
- chemotherapy, 65, 147–8, 153, 181, 219, 232–3
- children: behaviour, 58–9, 75, 106, 215, 239; cancers, 49–50, 58; conduct disorder, 125; development, 57–8, 81, 215; regulation of sales to, 172–3, 177
- chronic cannabis use: cognitive functioning, 79–81, 119; dependence, 74; health effects, 49–65, 131, 214–15; legalisation, 212; metabolism of cannabinoids, 15; prohibition and, 159, 186; psychological effects, 3, 67–100
- chronic health effects, 36–7, 131, 134–6
- cigarettes *see* tobacco
- civil sanctions, 185, 187, 190–4, 196, 212, 220–1
- cocaine *see* hard drugs (heroin and cocaine)
- cognitive effects, xii, xiii, 38, 69, 72, 75, 79–86, 87, 131, 134–5, 213, 215–16; adolescents, 118–20, 125, 132; early childhood, 58–9
- complementary drug use, 36–8, 56, 79–80, 83, 88, 93–5, 115, 144, 146, 153, 174, 208, 219
- conduct disorder, 122, 125
- confusion, 79, 88–9
- controlled substances, 188, 229
- corruption, 157, 172, 173, 218
- Costa Rica, 52, 60, 70, 79
- costs *see* economic costs
- crime: adolescents, 103, 105, 107, 124–5, 216; blackmarkets, 172–3, 218; cannabis use and, xiii, 236–9
- criminal justice resources: alternative market regimes, 9, 170, 193–4, 207, 212, 220; enforcement of prohibition, xi, 166, 175, 218
- criminal records, 1, 177–8, 187, 192, 194, 218, 224
- criminal sanctions, 1, 6, 185, 224; deterrence, 2, 160–2, 163–4, 169, 217; drug substitution, 146; economic studies, 111; enforcement costs, 166, 168–70, 176, 218; injustice and disproportion, 177–8; legal markets, 209–10, 212, 220, 222; medical use, 234; partial decriminalisation, 191–3, 196, 221, 229; prohibition models, 187–9, 194; *see also* decriminalisation
- cross-national comparisons, 7, 79–80, 146, 153

- Cuba, 188
cultivation: legal markets, 195–200, 202–4, 206–7; prohibition, 159, 162, 167, 170, 173–4, 185, 193, 239; *see also* home cultivation
- D**
daily use *see* frequency of use; heavy users
death *see* dosage; mortality
decriminalisation: crime and, 237; deterrence and, 220; drug substitution, 144–6; enforcement costs, 166, 169–70, 175; models, 187, 190–4, 196–7; policy debate, x, 2–3, 213, 217, 225, 232–3; reducing harms of use, 221–2; reform options, 219–20; supply, 221; use and, xi, 161–2, 175
delinquency, 58, 106, 117–18, 124–5, 239
delusions *see* psychotic disorders
demand, 112, 133, 144–6, 163, 166, 197–8, 201–2, 206–8, 219
Denmark, cannabis use in, 25, 28
dependence *see* cannabis dependence; drug dependence
depression, 36, 38, 70, 73, 91, 95, 98, 121–3, 143–4
deterrence: adults, 164; criminal sanctions, 2, 160–4, 179; decriminalisation and, 177, 208, 220, 225; prohibition of cannabis and, 157–9, 217–18
developmental effects, xi, 55–9, 101–25, 222, 224
deviant behaviour, 75, 105–6, 116–18, 125, 216
diathesis *see* genetic vulnerability
disrespect for law, 7, 9, 60–1, 157–8, 179, 181, 215, 218, 224–5
distress, 45, 75, 121–2, 143
distribution *see* supply
dopamine, 99
dosage, 14; acute effects, 36, 38, 213; cardiovascular effects, 60; cognitive functioning, 80; fatal overdoses, 17, 39, 45, 134, 213; health effects, 37, 51–2, 214; medical uses, 149; pharmacology, 110, 114; psychomotor tasks and, 45; toxic, 6, 39; withdrawal, 73
driving: accident risk, x, 39, 42–5, 124, 131, 133–4, 136, 141, 144, 208–9, 214, 224; inappropriate use of cannabis, 140, 164; psychomotor effects on, 16, 39, 40–2, 45, 213–14; regulation, 177, 197, 201–2, 209, 221; self-reported accidents, 44–5
dronabinol (Marinol), 65, 148, 227, 230
drop-outs, 106–7, 115, 119–20, 216; *see also* educational performance
drug abuse, 91–3, 97–8, 109, 138, 188
drug dependence, 71–2, 75–8, 98, 124, 132, 189–90; *see also* genetic vulnerability; tolerance; withdrawal
drug education *see* health education
drug interactions, 36; *see also* complementary drug use
drug policy *see* policy
drug subculture, 112, 114, 216
drug substitution, 144–6, 153, 219
DSM-IV, 71–2
duration of use, 6, 37, 80, 85, 140, 164, 186
dysphoria, 36, 38, 131
- E**
econometric evidence, 144, 153, 219
economic costs: drug abuse, 138–9; enforcement of prohibition, 158, 165–75, 181, 217–18, 220, 225
economic studies: cannabis as gateway drug, 111–12; legal markets, 195, 198–200, 223
economic substitution, 144–6, 153, 219
economically motivated crime, 237–8
educational performance, 25; adolescent cannabis use, xiii, 22, 70, 103, 106, 115–20, 125, 131–2, 135, 224; cannabis dependence, 75; cognitive functioning, 79–80; early school-leaving, 106–7, 115, 119–20, 216; explanations of relationships with cannabis use, 34, 116–17; longitudinal studies, 117–19
Egypt, 76, 79, 87
emetic use *see* anti-emetic use
employment, 25, 70, 75, 131, 135, 178, 187, 198, 218; adolescents, 103, 115, 118–21, 125
endogenous cannabinoids, 16–17
enforcement: cost of prohibition of cannabis supply, 165–8, 170–2, 173–5; cost of prohibition of cannabis use, 165, 166–70, 175; costs, 165, 166–70, 175, 181, 186, 220, 225, 234; costs and legal markets, 208, 209–10, 221, 224; drug substitution, 145; economic costs, 158, 165–75, 181, 217–18,

- 220, 225; legal markets, 196–201, 205, 209–12; medical uses, 234; policy of non-enforcement, 195–6; resources, 185; social costs, 218; unequal application, 169, 178–9, 181, 218; variations, 161–4, 188–9, 194
- epilepsy, 149–50, 233
- ethnicity, 146, 153, 178
- euphoria (high), 14, 36, 38, 60, 87, 98, 110, 142, 147, 176, 219
- Europe: cannabis dependence, 76; cannabis use, xi, 4, 25–9; policies, 165–7, 171, 193
- experimentation, 143–4, 164, 190, 223
- exposure opportunities, 108, 112–13, 190, 205, 211
- F**
- faintness, 39
- family circumstances, 29, 92, 107, 117–19, 163, 216
- family history *see* genetic vulnerability
- females: cancers, 48; cannabis dependence, 74, 76; educational performance, 115, 118; mental health, 123, 144; patterns of use, 21–4, 27; reproductive effects, 54, 59, 214–15 (*see also* pregnancy)
- fines *see* civil sanctions
- Finland, 25, 28
- flashbacks, 36, 132
- foetal development, 55–7
- food *see* appetite stimulation; oral administration
- France, 25, 28, 44, 96, 167
- frequency of use, 6, 85, 133, 140, 164; crime, 237; drug substitution, 146; employment, 120; gateway hypothesis, 107–8; health effects, 37; psychological effects, 80; suicide, 123; *see also* heavy users
- G**
- gaol *see* criminal sanctions
- gastrointestinal effects, 65, 135, 215
- gateway hypothesis, x, 103, 104–14, 125, 216; causal explanations of association, 105–14, 174; economic studies, 111–12; exposure opportunities, 112–13; genetic vulnerability to drug dependence, 106–9, 114; pharmacological hypotheses, 110–11, 114; selective recruitment, 106–9, 114; social environmental hypotheses, 112–14
- gender *see* females; males
- genetic vulnerability: drug dependence, 105, 106–9, 114, 216; psychosis (diathesis), 88–9, 97, 99, 131, 135
- Germany, x, 28, 161, 167, 191, 192, 237–8
- glaucoma, medical use of cannabis for, 149, 228
- government monopolies, 203–4, 206, 211, 224
- Greece, 28, 52, 79–80
- growth *see* developmental effects
- H**
- hallucinations *see* psychotic disorders
- hallucinogens, 37, 91, 97, 104, 109, 112–13, 133, 216
- hard drugs (heroin and cocaine): cardiovascular effects, 61; crack epidemic, 157; crime and delinquency, 124, 236–9; dependence, 71, 89; economic costs, 139; education, 180, 219; enforcement, 169, 171–4; evaluation of health risks, 5; international agreements, 1; patterns of use, 22, 105, 132; pregnancy, 81; psychotic disorders, 97; public health, 139–40; *see also* complementary drug use; drug substitution; gateway hypothesis
- harms of cannabis use, 9, 186; decriminalisation and, 1–3, 221–2; legalisation and, 211–12, 223–4; *see also* adverse health effects; cannabis abuse; cannabis dependence
- hash (hashish), 13–14, 17, 79, 192
- hash hungries *see* appetite stimulation
- hash oil, 13–14, 17
- health costs, 9, 139, 212; *see also* health service utilisation; public health
- health education, 3, 187, 190–2; cost of prohibition, 179–81, 219, 224; law reform, 140, 201, 221, 224–5
- health effects, x, xii, 1–4, 129, 213–17; alcohol and tobacco compared with cannabis, 129, 130–41; indirect, 131; policy and, 213, 216–17, 221–6; research, 5–7, 35, 37, 130, 139, 221–2, 225; *see also* adverse health effects
- health service utilisation, 43–4, 52, 59, 97, 121, 208
- heart conditions *see* cardiovascular effects

- heart rate, 16, 39, 60–1, 65, 215
heavy users, 14, 186; cardiovascular effects, 60; cognitive effects, 80–1, 85, 125; gender, 27; legalisation, 212
heroin *see* hard drugs (heroin and cocaine)
high *see* euphoria
HIV-AIDS: AIDS-related deaths, 44, 48, 53; immunological effects, 53, 59, 214; injecting drug users, 189; medical use, 65, 148–9, 154, 180–1, 215, 219, 228, 230, 232–3
home cultivation: law reform, 169, 196, 200, 203, 207, 210–11, 221, 225; medical use, 229–31, 233–4
homosexual men, 44, 53, 59, 149
hospitalisation *see* health service utilisation
hypertension, 60, 65, 132, 215
hypnotic effects, 147
- I
illicit drugs *see* hard drugs (heroin and cocaine)
immunocompromised persons, 53, 59, 148–9
immunological effects, 17, 37, 50–3, 58–9, 214
importation and smuggling, 170–1, 188, 190, 195, 199, 207
India, 4, 14, 87–8, 146
individual characteristics *see* personality and attitudinal traits
individual liberty *see* liberty
industrial hemp, 168, 196–7, 207
infectious diseases, 52, 58, 149, 214
information processing, 81–3, 119, 215
injection, 14, 147
international agreements, 1, 7, 195, 222–3, 225
international comparisons *see* cross-national comparisons
interpersonal relationships, 103, 121
intoxicants, 6, 106, 114
intoxication, 6, 17; acute effects, 131–5, 213–14; adolescents, 103, 119, 125, 132, 209; alcohol, 42, 45, 157; cannabinoids, 16–17, 132–3; chronic, 120; delinquency, 124; psychological effects, 38, 71–2, 74–5, 80; psychomotor effects, 39–42; rates of use, 186
IQ, 57–8, 81, 83, 93
Ireland, 28
Italy, 166, 193
- J
Jamaica, 14, 28, 52, 60, 70, 79–80
joints, 14, 17, 25
- L
law reform *see* policy
learning, 83, 115
legal markets, 185–6, 211–12, 217; effects on use, 198–201, 223; enforcement, 168, 174; monetary price, 205–7; potential models, 195–7, 198; regulation and social norms, 201–7; social costs, 207–10; social costs of enforcement, 209–10; social costs of use, 208–9
legal risk, 135, 160–2, 172, 174, 199–200, 207
legalisation: alcohol and tobacco compared with cannabis, 129; *de facto*, 194; enforcement costs, 175; legal obstacles to, 222–3; medical uses, 227–9, 234; policy debate, 195–212, 213, 222, 225; proposals for, 2, 197–201; public health, 140; rates of use and, 223; reducing harms of use, 223–4
liberty, 7–8, 158, 176–7, 181, 219, 224–5
licensing systems, 196–7, 203–4, 206–7, 210–11, 221, 224
liver function, 65, 135, 157, 208, 215
long-term effects *see* chronic health effects
long-term users *see* chronic cannabis use
lung cancer, 47, 62, 65, 137
lungs, effects on, 52, 62–3, 65, 135, 151, 214, 228
- M
males: cancers, 48; cannabis dependence, 74, 76; cognitive functioning, 79; delinquency, 124; educational performance, 115, 118; patterns of use, 22–5, 27–8, 90; reproductive effects, 54–5, 59, 214–15; self-harmful behaviour, 123
marijuana, 13–14, 17
Marinol (dronabinol), 65, 148, 227, 230
markets *see* blackmarkets; legal markets
marriage, 21–2, 29, 120–1
medical care *see* health service utilisation
medical uses: benefits, 129, 146–54, 219; biology, 17; debate on, 4, 227–35; history, 14; initiatives, x, 188, 193, 229–32, 233–4;

- loss of, under prohibition, 7, 180–1, 224;
obstacles to, 153, 234–5; psychological
effects, 38; registration for, 228–9, 231; *see also* appetite stimulation
- memory, 17, 38, 58, 76, 79–80, 83, 85, 87–9,
115, 131, 135, 213, 215
- mental health, xii, 87; adolescents, 103, 117,
121–3, 125, 216; benefits of cannabis use,
142–4, 153, 219; *see also* psychotic
disorders
- metabolites, 15–17, 42, 44
- Mexico, 188
- Middle East, 146
- monetary costs *see* economic costs
- monetary price *see* price
- monopolies, 203–4, 206, 211, 224
- mood, 17, 39, 73, 122, 143
- moral theories, 5–6, 8–9
- morbidity, 130, 138–40
- mortality, 43–4, 130, 135, 138–9, 142, 208,
213–14, 222
- motivational effects, 69–71, 75, 78, 119
- motor performance, 17, 38, 150–1
- motor vehicle accidents *see* driving
- movement disorders, 149, 150–1
- multiple sclerosis (MS), 149–51, 180–1,
232–3
- munchies *see* appetite stimulation
- muscle spasticity *see* anti-spasmodic use
- mutagenicity, 46–50, 58, 64
- N**
- nabilone, 227
- narcotic drugs, 1, 91, 124, 147
- nausea *see* anti-emetic use
- Netherlands, xi, 7, 28, 94, 161, 163, 194–6,
204, 222–3, 237–8
- neural systems, 39, 110, 114, 151
- neuroleptic drugs, 87, 92, 96, 99
- neurological disorders, 149–51, 180–1, 232–3;
see also anti-spasmodic use
- neurotoxicity, 84–5
- New Zealand: adolescent cannabis use, 105–7,
113, 116–17, 122, 125; cannabis
dependence, 74; driving accidents, 45;
enforcement, 178; mental health, 143;
psychotic effects, 88–9, 95; respiratory
effects, 64
- nicotine *see* tobacco
- Norway, 26, 28
- O**
- occupational performance *see* employment
- Oceania, 26–7
- opiates, 72, 79, 107, 138–9, 147
- opioids, 6, 71, 109–11, 114, 151
- opportunity costs, 166, 170
- oral administration, 14–15, 38, 73, 140, 147,
149, 151, 227–8
- overdose *see* dosage
- P**
- pain modulation *see* analgesic effects
- panic, 36, 38, 131, 209, 213
- paranoia, 131
- parents *see* family circumstances
- peer groups, 107–8, 112–15, 117–18, 120–1,
124–5, 216
- penalties, 7, 162–3, 185, 188–94, 208, 218,
220, 222; *see also* civil sanctions; criminal
sanctions; treatment
- perceptual alterations, 38, 58, 96
- personality and attitudinal traits, 103, 105–8,
112, 114, 117, 131, 134, 239
- pharmaceutical drugs, 65, 147–8, 153, 188,
227–8, 230, 235
- pharmacology: effects, 6, 237–8; gateway
hypothesis, 105, 110–11, 112, 114, 174,
216; medical uses, 151, 153
- 'pills' *see* amphetamines; tranquillisers
- policing: enforcement of prohibition, 167–71,
175, 189–90, 217–18, 224; legal markets,
193–4, 199–200, 209, 212; quality-of-life,
168, 171, 209
- policy: alternatives, 7, 9, 172, 183–226 (*see also*
decriminalisation; legalisation;
prohibition of cannabis); changes, 144,
161–2, 175; choice of evils, 224–6; debate,
xii, 1–5, 7–9, 129, 157–8, 179, 181, 187,
213, 225–6; drug involvement patterns,
105; economic studies, 111; effect on use,
161–3; health effects and, 216–17;
prevention, 111; reform, x, 157, 219–24;
research, 4, 226; simplifications, 2–3, 213,
216, 226
- Portugal, 28, 166–7, 193–4
- possession: legal, 195, 197, 202, 208, 225;
offences, xi, 159–62, 165–9, 175, 185,
187–94, 196, 222, 229, 237
- potency, 14, 17, 173, 197, 205, 218, 221, 223;
control, 204, 209; increases in, 13, 132, 133

- poverty *see* socioeconomic status
- pregnancy: alcohol use, 134; cannabis use during, 21–2, 49–50, 54–9, 81, 131–2, 134, 137, 141, 214–15; health education, 201; inappropriate use of cannabis, 164; teenage, 106, 119–21; *see also* birth defects; birth weight
- premature death *see* mortality
- prevention studies, 111
- price: blackmarkets, 161–2, 172, 211, 238; economic studies, 111, 144–6; legal markets, 9, 174–5, 198–200, 205–7, 208–12, 223
- prohibition of alcohol, 7, 157–8, 188, 190
- prohibition of cannabis: benefits, 157–8, 163–4; complete, 187–90; costs, 163–4, 176–81, 213, 217–20, 224–5; crime, 236, 238; deterrence and, 175, 179, 217–18, 220; enforcement (*see* enforcement); impact on use, 159–64; medical use and, 227; policy, 1–3, 6–7, 157, 185, 194, 198, 209, 211, 213; public health, 140, 216–17; social costs, 157–8; variants, 185, 187–94
- psychiatric disorders, 70–2, 81–2, 89, 91–5, 121, 123–4, 135
- psychoactive drugs, 6, 22, 71, 130
- psychoactive effects, 4, 13, 15–17, 36, 51, 87–91, 148, 151–2, 236
- psychological effects, 17, 129, 131–3, 221–3; acute, 38, 45, 119, 213–14; adolescents, 35, 103, 115–25, 216; animal studies, 34; chronic cannabis use, 67–100, 213–16; *see also* cognitive effects
- psychomotor effects, 16–17, 38, 45, 72, 119, 131, 134, 209, 213–14
- psychopharmacology, 236–7
- psychostimulants, 6, 75, 91, 96–7, 109–10, 123
- psychotic disorders: acute effects of cannabis use, 36, 38, 131, 213; adolescents, 121–2; alcohol, 157; causal inferences, 87, 88; chronic cannabis use, 69, 87–100, 135, 216; regulation, 209, 222–4; symptoms, 89–90, 99; treatment, 97; vulnerability to, 95–6, 99, 131, 216; *see also* 'cannabis psychosis'; schizophrenia
- public education *see* health education
- public health: burden of disease, 139–40; changes in prevalence of cannabis use, 140; current patterns of use, 141; immunological effects, 50, 52; impact of alcohol, tobacco and illicit drugs, 129–30, 136–7, 138–40, 144; policy, 6, 205
- public policy *see* policy
- Q
- quality control, 9, 172–3, 177, 209, 222
- R
- race and ethnicity, 146, 153, 178
- rates of use: decriminalisation and, 220, 225; Europe, xi; legalisation and, 140, 197–8, 200, 204, 207–8, 211–12, 223; policy and, 159, 162–3, 168–9, 171, 186
- receptors *see* cannabinoid receptors
- recreational use: benefits, ix, 129, 142–6, 153, 176, 219; biology, 17; dysphoric effects, 36, 38, 131; effects sought, 36, 38; enforcement of prohibition, 168–9; history, 21–2, 29, 188; legalisation, 198, 208; medical use and, 147, 149–50, 227–9, 232, 234; policy, x, 4, 129
- registration for medical use, 228–9, 231
- regulation, 9, 173–5, 177, 185–6, 198–207, 208–10, 212, 221–2, 224–5; *see also* licensing systems
- relaxation, 36, 38, 142, 176, 213, 219
- reproductive effects, 17, 53–8, 214–15
- reputation *see* criminal records
- respect for law *see* disrespect for law
- respiratory tract: cancers, 48, 58, 64, 136–7, 141, 214–15, 222; effects on, 17, 52, 59, 61–4, 131–7, 141, 215, 222, 224; health education, 201, 221
- retail markets, 173–4, 194–6, 203–4, 223, 225
- risk-taking behaviour, 107, 118, 140
- risks of cannabis use, 130, 136–8
- S
- sale *see* supply
- schizophrenia, 69, 89; association with cannabis use, 87–8, 91–2; exacerbation, 96–7, 99, 132; health education, 201; precipitation of, 92–6, 99, 132, 135, 216; research, 90–1, 98–9; risks, 94, 132, 137, 141; self-medication, 98; treatment, 99; violence, 125
- school leaving, 106–7, 115, 119–20, 216; *see also* educational performance
- sedatives, 91, 109, 123
- selective recruitment, 106–8, 114
- self-esteem, 75–6, 107

- self-medication, 98, 122
- sensitisation *see* pharmacology
- sequence of drug use *see* gateway hypothesis
- sexual behaviour, 38, 53, 105–7, 118–19
- smoking *see* cannabis smoking; tobacco
- smuggling *see* importation and smuggling
- sociability, 38, 98, 114, 142, 176, 213, 219
- social costs: cannabis-control policies, 7–9, 186, 191; comparisons with alcohol and tobacco, 138; enforcement of prohibition, 165, 171–3, 217–18; law reform, 2, 197–8, 200–1, 207–10
- social environment: cannabis as gateway drug, 105, 109, 112–13, 114; educational performance, 117, 120, 125; interpersonal relationships, 121; suicide, 123
- social norms: health education, 180, 190; legal markets and regulation, 140, 197–8, 200, 201–7, 212, 222–3, 225–6; regulating demand, 163, 201–2; regulating supply, 202–5; values, 8–9
- social performance *see* psychological effects
- social policy *see* policy
- socioeconomic status, 28, 70, 107, 117, 123, 178
- South Africa, 88
- South America, 26–8
- Spain, 25, 28, 166, 193
- special case, cannabis as, 3, 6
- spinal cord injuries, 149–50, 233
- stepping stone hypothesis *see* gateway hypothesis
- stimulants, 6, 75, 91, 96–7, 109–10, 123
- subculture, 112, 114, 216
- substance dependence *see* drug dependence
- substitution, 144–6, 153, 219
- suicide, 122, 123–4, 134–5
- supply: law reform, 161, 185–6, 195–9, 202–6, 220–2, 224; medical uses, 234; prohibition, 159, 175, 185, 187–8, 190, 193, 195–6, 234 (*see also* enforcement); *see also* cultivation
- Sweden, 25, 28, 43, 88, 92–4, 179, 187–8, 189–90
- Switzerland, x, 25–6, 122, 143, 167–9, 178, 194, 197, 205, 207; *de facto* legalisation, 196
- T**
- taxation: blackmarket and, 166, 172, 174–5, 219, 225; economic studies, 111, 144; legal markets, 199–200, 206–7, 211, 222–3
- THC *see* cannabinoids
- thinking *see* cognitive effects
- tobacco: deaths caused by fires, 131; dependence, 75, 78, 109; drug substitution, 146; gateway hypothesis, 104, 106–7, 110–11, 113, 216; health effects, 6, 37, 44, 47–50, 61–4, 129, 130–41, 215, 217, 221; market regulation, 199, 201–2, 205, 207–8, 222; mental health, 90, 98, 121–2; patterns of use, 21–2, 160, 211; policy, 3, 223–4; pregnancy, 215; price, 212; risks, 141; smoke, 47, 58, 131, 134, 214–15; used with cannabis, 14, 56–8, 84
- tolerance of effects, 52, 58, 60–1, 71–4, 78, 133, 149, 214–15
- toxicity *see* dosage
- tranquillisers, 37, 93, 104, 112–13, 216
- treatment, 185, 187, 189–94, 220
- tremors and startle, 57–8, 150–1
- U**
- unemployment *see* employment
- United Kingdom: cannabis use in, xi, 25–6, 28, 159–60; crime, 236; medical uses, 147, 227–8, 232, 234–5; policies, 1, 166–7; psychotic effects, 88; reproductive effects, 56
- United States: adolescent cannabis use, 103–5, 112–13, 115, 118, 122–4, 211; alcohol prohibition, 7, 157; cannabis dependence, 73–4, 76, 78, 137–8; cannabis prohibition, 187, 188–9; cannabis use, 4, 18–19, 18–22, 19–23, 26–9, 145, 159–63, 208; crime, 236–9; driving accidents, 42; drug dependence, 78; drug substitution, 145–6; federal-state conflicts, 192–3, 229–32, 234; health effects, 53, 131; health service use, 208; home cultivation, 210, 229–31; medical uses, x, 147–9, 180–1, 227–8, 229–32, 234–5; policies, x–xi, 1, 165–8, 170–5, 178–9, 187–9, 191–3, 197–205, 220; potency of cannabis, 13, 133; psychological effects, 70, 79, 99, 143–4; taxation, 207
- urine, detection of cannabinoids in, 16–17, 83
- use: controlling, 78; costs of, 186; crime and, 236–9; discontinuance, 75, 159; duration (*see* duration of use); experimentation, 143–4, 164, 190, 223; factors associated with, 26–8; frequency (*see* frequency of use); inappropriate, 164; law reform, 163,

Cambridge University Press

978-0-521-80024-2 - Cannabis Use and Dependence: Public Health and Public Policy
Wayne Hall and Rosalie Liccardo Pacula

Index

[More information](#)

298

Index

198–201, 208–9, 222; measuring, 18–26;
occasional and intermittent, 23, 159, 164,
192, 194, 208; offences, x, 175; patterns of,
18–29, 105, 133, 140–1, 178, 198, 223;
prohibition, 159–64, 185, 187–94 (*see also*
enforcement); rates (*see* rates of use);
research on, 4; restrictions on, 197, 202;
trends, 18, 20, 23–5, 140; *see also* benefits
of cannabis use; harms of cannabis use;
possession

V

values, 8–9

violence and aggression: alcohol use, 131,
134–5, 144, 237; cannabis use, 96, 124–5,
236–7; market-related, 166, 172, 238–9;
withdrawal, 73

visual system, 57–8; *see also* glaucomavomiting *see* anti-emetic usevulnerability *see* genetic vulnerability

W

water pipes (bongs), 14, 17, 25

weight gain *see* appetite stimulationwithdrawal, 71–4, 76–8, 134–5, 138, 215,
238

Y

young adults: cancer, 214; cannabis
dependence, 78; cannabis use, 1, 18–29,
188; cardiovascular effects, 60–1, 215;
drug substitution, 144–6; employment,
120–1; gateway hypothesis, 105, 112–13;
interpersonal relationships, 121;
legalisation and use, 212; mental health,
122–3, 144; prohibition and, 159–60;
public health, 50, 141; reproductive
effects, 53–4; respiratory effects, 62–3;
schizophrenia, 99; *see also* disrespect for
law

youth *see* adolescents